Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jerry W. Call
Observed names:
Call, Jerry,
Call, Jerry W.,
J. Call,
Jerry Call
Institution:
Life Raft Group
Observed institution:
Life Raft Group
ORCID:
0000-0001-9110-8241
Observed ORCID:
0000-0001-9110-8241
OpenAlex ID:
A5011130858
Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry
2012
·
Jerry Call
, Christopher D Walentas
, et al.
·
BMC Cancer
·
49
PDF
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
2019
·
Michael C. Heinrich
, Janice Patterson
, et al.
·
Clinical Sarcoma Research
·
47
PDF
Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
2019
·
Jerry W. Call
, Yu Wang
, et al.
·
Clinical Sarcoma Research
·
32
PDF
Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study
2009
·
Jerry Call
, Norman J. Scherzer
, et al.
·
Journal of Gastrointestinal Cancer
·
12
PDF
Mutational Testing in Gastrointestinal Stromal Tumor
2019
·
Yu Wang
, Jerry Call
·
Current Cancer Drug Targets
·
11
Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members
2022
·
Denisse Montoya
, Jerry W. Call
, et al.
·
BMC Gastroenterology
·
3
PDF
Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
2019
·
Jerry W. Call
, Yu Wang
, et al.
·
Clinical Sarcoma Research
·
3
PDF
1758P Real-world efficacy of imatinib in patients with advanced GIST: The LRG registry
2024
·
G. Gim
, J. Call
, et al.
·
Annals of Oncology
·
2
PDF
1978P Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
2023
·
D. Evans
, J. Call
, et al.
·
Annals of Oncology
·
2
PDF
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry
2023
·
Jerry Call
, Jonathan Wojtkowiak
, et al.
·
Cancer Investigation
·
2
PDF
Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type
2022
·
Annalisa Astolfi
, Anthony Gill
, et al.
·
Pathology
·
1
PDF
Diagnostic algorithm for gastrointestinal stromal tumor (GIST) using patient registry data impacts pathology guidelines.
2020
·
Sara Rothschild
, Jerry Call
, et al.
·
Journal of Clinical Oncology
·
1
The benefits of patient-centered patient registries.
2017
·
Michelle Durborow
, Kathrena Aljallad
, et al.
·
Journal of Clinical Oncology
·
1
Supplementary Table S5 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supp. Fig. 2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Figure 2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supplementary Table S4 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supplementary Table S6 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supplementary Table S2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supp. Fig. 6 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Figure 4 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supplementary Table S7 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supplementary Table S3 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supp. Fig. 4 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Supp. Fig. 5 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026
·
Homma M. Khosroyani
, Alina Teuber
, et al.
Show more works
View as search
Works count:
54
Citation count:
166
H-index:
5
I10-index:
5
Year
Topic
Type
